These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 1790357)

  • 21. Test for ability of decay-accelerating factor (DAF, CD55) and CD59 to alleviate complement-mediated damage of xeno-erythrocytes.
    Miyagawa S; Shirakura R; Matsumiya G; Nakata S; Matsuda H; Hatanaka M; Matsumoto M; Kitamura H; Seya T
    Scand J Immunol; 1993 Jul; 38(1):37-44. PubMed ID: 7687071
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and Genetic Spectrum of a Large Cohort With Total and Sub-total Complement Deficiencies.
    El Sissy C; Rosain J; Vieira-Martins P; Bordereau P; Gruber A; Devriese M; de Pontual L; Taha MK; Fieschi C; Picard C; Frémeaux-Bacchi V
    Front Immunol; 2019; 10():1936. PubMed ID: 31440263
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erythrocytes of patients with paroxysmal nocturnal haemoglobinuria acquire resistance to complement attack by purified 20-kD homologous restriction factor.
    Okada N; Harada R; Okada H
    Clin Exp Immunol; 1990 Apr; 80(1):109-13. PubMed ID: 1691059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.
    Medof ME; Kinoshita T; Nussenzweig V
    J Exp Med; 1984 Nov; 160(5):1558-78. PubMed ID: 6238120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria.
    Pangburn MK; Schreiber RD; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1983 Sep; 80(17):5430-4. PubMed ID: 6225118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complement polymorphism, the major histocompatibility complex and associated diseases: a speculation.
    Porter RR
    Mol Biol Med; 1983 Jul; 1(1):161-8. PubMed ID: 6679872
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polymorphism of the complement components in human pathology.
    Brai M; Accardo P; Bellavia D
    Ann Ital Med Int; 1994; 9(3):167-72. PubMed ID: 7946894
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical significance of complement deficiencies.
    Pettigrew HD; Teuber SS; Gershwin ME
    Ann N Y Acad Sci; 2009 Sep; 1173():108-23. PubMed ID: 19758139
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complement regulators in human disease: lessons from modern genetics.
    Liszewski MK; Atkinson JP
    J Intern Med; 2015 Mar; 277(3):294-305. PubMed ID: 25495259
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Normal function of CR1 on affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria.
    Roberts WN; Wilson JG; Wong W; Jenkins DE; Fearon DT; Austen KF; Nicholson-Weller A
    J Immunol; 1985 Jan; 134(1):512-7. PubMed ID: 2578050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Complement deficiency and lupus erythematosus].
    Borradori L; Nydegger U
    Rev Med Suisse Romande; 1992 Apr; 112(4):355-62. PubMed ID: 1594866
    [No Abstract]   [Full Text] [Related]  

  • 32. Molecular mapping of the HLA-linked complement genes and the RCA linkage group.
    Campbell RD; Dunham I; Sargent CA
    Exp Clin Immunogenet; 1988; 5(2-3):81-98. PubMed ID: 3155403
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retrovirus-mediated over-expression of decay-accelerating factor rescues Crry-deficient erythrocytes from acute alternative pathway complement attack.
    Kim DD; Miwa T; Song WC
    J Immunol; 2006 Oct; 177(8):5558-66. PubMed ID: 17015743
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complement genetics and host defence.
    Lachmann PJ
    Zentralbl Bakteriol; 1990 Dec; 274(3):316-24. PubMed ID: 2151023
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decay-accelerating factor. Genetic polymorphism and linkage to the RCA (regulator of complement activation) gene cluster in humans.
    Rey-Campos J; Rubinstein P; Rodriguez de Cordoba S
    J Exp Med; 1987 Jul; 166(1):246-52. PubMed ID: 2439634
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure, organization, and regulation of the complement genes.
    Campbell RD; Law SK; Reid KB; Sim RB
    Annu Rev Immunol; 1988; 6():161-95. PubMed ID: 2898251
    [No Abstract]   [Full Text] [Related]  

  • 37. Complement deficiencies.
    Colten HR; Rosen FS
    Annu Rev Immunol; 1992; 10():809-34. PubMed ID: 1591004
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The complement system in systemic autoimmune disease.
    Chen M; Daha MR; Kallenberg CG
    J Autoimmun; 2010 May; 34(3):J276-86. PubMed ID: 20005073
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transcriptional control of complement receptor gene expression.
    Martin BK
    Immunol Res; 2007; 39(1-3):146-59. PubMed ID: 17917062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Two modes of homologous C3 deposition on Ramos Burkitt's lymphoma cell substrains co-expressing DAF (CD55), CD59, and CR2 (CD21), and on cells lacking them.
    Seya T; Hara T; Okada M; Kojima A; Matsumoto M; Akedo H
    Int Immunol; 1992 Dec; 4(12):1361-71. PubMed ID: 1283697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.